{"gene":"CSGALNACT1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2002,"finding":"CSGalNAcT-1 (CSGALNACT1) is a type II membrane protein with N-acetylgalactosaminyltransferase activity that initiates chondroitin sulfate (CS) chain synthesis by transferring GalNAc to the tetrasaccharide GAG-protein linker region (GlcA-Gal-Gal-Xyl-O-methoxyphenyl) with beta-1,4 linkage. Transfection of CSGalNAcT-1 into CHO cells shifted glycosaminoglycan composition on a syndecan-4/FGF-1 chimera from heparan sulfate to chondroitin sulfate, confirming its role in CS chain initiation in vivo.","method":"In vitro enzyme activity assay with CS poly/oligosaccharide substrates; CHO cell transfection with glycosaminoglycan composition analysis; 5'-RACE cloning","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic assay, cell-based transfection with defined biochemical readout, replicated substrate specificity comparisons","pmids":["12446672"],"is_preprint":false},{"year":2016,"finding":"A missense mutation p.Pro384Arg in CSGALNACT1 causes reduced GalNAc-transferase activity of the CSGalNAcT-1 protein, establishing that this catalytic activity is required for normal CS chain biosynthesis and skeletal development; loss-of-function mutations cause a skeletal dysplasia reminiscent of Csgalnact1-/- mice.","method":"Biochemical GalNAc-transferase activity assay of mutant vs wild-type recombinant protein; clinical genetics (compound heterozygosity identified by sequencing); fibroblast proteoglycan synthesis analysis","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct enzymatic activity assay of mutant protein, supported by clinical genetics and mouse model consistency, single lab","pmids":["27599773"],"is_preprint":false},{"year":2017,"finding":"CSGalNAcT1 (T1) knockout mice show ~50% reduction in CS content in brain regions, with diminished CS in perineuronal nets (PNNs) despite unchanged aggrecan core protein levels, demonstrating that CSGalNAcT1 is required for CS chain biosynthesis in PNNs and is necessary for normal ocular dominance plasticity onset and social/behavioral phenotypes.","method":"CSGalNAcT1 knockout mouse generation; biochemical quantification of CS by ELISA/disaccharide analysis; immunohistochemistry for PNN components; behavioral testing (open-field, acoustic startle, social preference)","journal":"Molecular brain","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse with defined biochemical and behavioral phenotypes, multiple orthogonal methods across independent labs","pmids":["28982363","28987564"],"is_preprint":false},{"year":2017,"finding":"CSGalNAcT1 (T1) knockout mice show extensive axon regeneration following spinal cord injury, establishing that CS synthesized by T1 creates a physical and chemical barrier inhibiting axon growth after CNS injury.","method":"Spinal cord injury in T1 knockout mice with axon regeneration assessment","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined KO with specific cellular phenotype (axon regeneration), single lab, no orthogonal mechanistic confirmation in abstract","pmids":["28987564"],"is_preprint":false},{"year":2016,"finding":"A coding SNP in CSGalNAcT-1 (p.S126L) results in complete loss of enzyme activity when expressed in COS-1 cells, identifying Ser-126 as functionally critical for catalytic activity.","method":"Expression of mutant ChGn-1 protein in COS-1 cells with GalNAc-transferase activity assay","journal":"Neuroscience research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct enzyme activity assay in cells, single lab, single method reported in abstract","pmids":["26806424"],"is_preprint":false},{"year":2019,"finding":"Novel missense variants p.Asp432Tyr and p.Asn264Ser in CSGALNACT1 result in significantly reduced CSGalNAcT-1 enzymatic activity, and patient fibroblasts show altered levels of chondroitin, dermatan, and heparan sulfate moieties, confirming that loss of CSGalNAcT-1 activity disrupts glycosaminoglycan biosynthesis.","method":"Biochemical GalNAc-transferase activity assay of recombinant mutant proteins; disaccharide analysis of GAG composition in patient fibroblasts; trio-exome sequencing","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct enzyme activity assay and cell-based GAG composition analysis, two orthogonal methods, single lab","pmids":["31705726"],"is_preprint":false},{"year":2026,"finding":"CSGALNACT1 overexpression in Neuro2a cells enhances CS-dependent tau seed uptake, and CSGALNACT1-generated CS (enriched in non-sulfated O-unit disaccharides) shows high affinity for tau seeds and wild-type tau monomers and promotes tau aggregation in vitro, establishing that O-unit-enriched CS chains produced by CSGALNACT1 facilitate extracellular tau capture, cellular uptake, and aggregation.","method":"CSGALNACT1 overexpression in Neuro2a cells with tau seed uptake assay; disaccharide analysis of CS composition; in vitro tau aggregation assay with CS; CS-tau binding affinity measurement","journal":"Biochimica et biophysica acta. General subjects","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct in vitro binding and aggregation assays plus cell-based uptake assay with overexpression, multiple orthogonal methods, single lab","pmids":["41996943"],"is_preprint":false}],"current_model":"CSGALNACT1 (CSGalNAcT-1/ChGn-1) is a Golgi-resident type II membrane GalNAc-transferase that catalyzes the initial step of chondroitin sulfate (CS) chain biosynthesis by transferring GalNAc in a beta-1,4 linkage to the GAG-protein linker tetrasaccharide; it generates O-unit-enriched CS chains that regulate perineuronal net formation, CNS axon regeneration inhibition after injury, synaptic plasticity, and—via high-affinity binding to tau—can facilitate tau seed uptake and aggregation, with loss-of-function mutations in humans causing skeletal dysplasia."},"narrative":{"mechanistic_narrative":"CSGALNACT1 (CSGalNAcT-1/ChGn-1) is a Golgi-type N-acetylgalactosaminyltransferase that initiates chondroitin sulfate (CS) chain biosynthesis by transferring GalNAc in a beta-1,4 linkage onto the GlcA-Gal-Gal-Xyl GAG-protein linker tetrasaccharide; ectopic expression shifts glycosaminoglycan output from heparan sulfate toward chondroitin sulfate, confirming its role in committing chains to the CS pathway in vivo [PMID:12446672]. This catalytic activity is functionally critical: point mutations at residues such as Ser-126, Asn-264, Pro-384, and Asp-432 abolish or sharply reduce GalNAc-transferase activity and disrupt glycosaminoglycan composition in patient fibroblasts [PMID:27599773, PMID:26806424, PMID:31705726], and biallelic loss-of-function variants in humans cause a skeletal dysplasia [PMID:27599773, PMID:31705726]. In the CNS, CSGalNAcT1 supplies CS chains for perineuronal nets, and its loss reduces brain CS by roughly half without affecting the aggrecan core protein, altering ocular dominance plasticity and social behavior [PMID:28982363, PMID:28987564], while also generating the inhibitory CS barrier that limits axon regeneration after spinal cord injury [PMID:28987564]. The CS chains produced by CSGalNAcT1 are enriched in non-sulfated O-unit disaccharides, which bind tau seeds and monomers with high affinity and promote tau capture, cellular uptake, and aggregation [PMID:41996943].","teleology":[{"year":2002,"claim":"Established the founding biochemical activity: whether CSGalNAcT-1 initiates CS chain assembly was answered by showing it adds the first GalNAc to the linker tetrasaccharide and redirects GAG output toward chondroitin sulfate.","evidence":"In vitro GalNAc-transferase assay on linker substrates plus CHO transfection with GAG composition analysis on a syndecan-4/FGF-1 chimera","pmids":["12446672"],"confidence":"High","gaps":["Structural basis of substrate recognition not resolved","Relative contribution versus CSGalNAcT-2 in vivo not addressed"]},{"year":2016,"claim":"Connected enzyme activity to disease and pinpointed catalytic residues: missense mutations (p.Pro384Arg; p.S126L) reduce or abolish GalNAc-transferase activity, establishing that the catalytic function is required for CS biosynthesis and skeletal development.","evidence":"Biochemical activity assays of recombinant/cell-expressed mutant proteins, clinical genetics, and fibroblast proteoglycan analysis","pmids":["27599773","26806424"],"confidence":"Medium","gaps":["Single-lab activity measurements","Structural explanation for residue criticality not provided"]},{"year":2017,"claim":"Defined the CNS requirement: knockout mice resolved whether CSGalNAcT1 is needed for CS in perineuronal nets and for plasticity, showing ~50% brain CS loss, depleted PNN CS, and altered ocular dominance plasticity and behavior.","evidence":"Knockout mouse with CS quantification, PNN immunohistochemistry, and behavioral testing","pmids":["28982363","28987564"],"confidence":"High","gaps":["Mechanism linking CS loss to specific behavioral phenotypes not dissected","Cell-type-specific contributions not isolated"]},{"year":2017,"claim":"Linked the enzyme to injury repair: knockout mice showed extensive axon regeneration after spinal cord injury, establishing that CSGalNAcT1-synthesized CS forms an inhibitory barrier to CNS axon growth.","evidence":"Spinal cord injury in knockout mice with axon regeneration assessment","pmids":["28987564"],"confidence":"Medium","gaps":["No orthogonal mechanistic confirmation of the inhibitory mechanism","Functional recovery outcomes not detailed"]},{"year":2019,"claim":"Broadened the disease/biochemistry link: additional missense variants (p.Asp432Tyr, p.Asn264Ser) reduce activity and disrupt chondroitin, dermatan, and heparan sulfate moieties in patient cells, confirming loss of activity perturbs glycosaminoglycan biosynthesis broadly.","evidence":"Recombinant mutant activity assays, fibroblast disaccharide analysis, and trio-exome sequencing","pmids":["31705726"],"confidence":"Medium","gaps":["Single-lab study","Genotype-phenotype correlation across patients not established"]},{"year":2026,"claim":"Defined a disease-relevant downstream consequence: O-unit-enriched CS produced by CSGALNACT1 binds tau with high affinity and promotes its capture, uptake, and aggregation, linking the enzyme's chain output to tau pathology.","evidence":"Overexpression in Neuro2a cells with tau seed uptake assay, CS disaccharide analysis, in vitro tau aggregation, and CS-tau binding affinity measurement","pmids":["41996943"],"confidence":"Medium","gaps":["Single-lab in vitro/cell evidence not validated in vivo","Relevance to human tauopathy progression not established"]},{"year":null,"claim":"How CSGalNAcT1 activity is regulated, how O-unit-enriched chain composition is controlled, and the structural basis of its substrate specificity remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model in the corpus","Regulation of chain sulfation pattern uncharacterized","Functional division of labor with CSGalNAcT-2 unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,4,5]}],"localization":[],"pathway":[],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8TDX6","full_name":"Chondroitin sulfate N-acetylgalactosaminyltransferase 1","aliases":["Chondroitin beta-1,4-N-acetylgalactosaminyltransferase 1","Beta4GalNAcT-1"],"length_aa":532,"mass_kda":61.3,"function":"Transfers 1,4-N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of glucuronic acid (GlcUA). Required for addition of the first GalNAc to the core tetrasaccharide linker and for elongation of chondroitin chains. Important role in chondroitin chain biosynthesis in cartilage formation and subsequent endochondral ossification (PubMed:11788602, PubMed:12163485, PubMed:12446672, PubMed:17145758, PubMed:31705726). Moreover, is involved in the metabolism of aggrecan (By similarity)","subcellular_location":"Golgi apparatus, Golgi stack membrane","url":"https://www.uniprot.org/uniprotkb/Q8TDX6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CSGALNACT1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CSGALNACT1","total_profiled":1310},"omim":[{"mim_id":"618870","title":"SKELETAL DYSPLASIA, MILD, WITH JOINT LAXITY AND ADVANCED BONE AGE; SDJLABA","url":"https://www.omim.org/entry/618870"},{"mim_id":"616616","title":"CHONDROITIN SULFATE N-ACETYLGALACTOSAMINYLTRANSFERASE 2; CSGALNACT2","url":"https://www.omim.org/entry/616616"},{"mim_id":"616615","title":"CHONDROITIN SULFATE N-ACETYLGALACTOSAMINYLTRANSFERASE 1; CSGALNACT1","url":"https://www.omim.org/entry/616615"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"thyroid gland","ntpm":70.7}],"url":"https://www.proteinatlas.org/search/CSGALNACT1"},"hgnc":{"alias_symbol":["CSGalNAcT-1","FLJ11264","ChGn"],"prev_symbol":[]},"alphafold":{"accession":"Q8TDX6","domains":[{"cath_id":"-","chopping":"143-258","consensus_level":"high","plddt":89.592,"start":143,"end":258},{"cath_id":"3.90.550.10","chopping":"264-509","consensus_level":"high","plddt":95.0763,"start":264,"end":509}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TDX6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TDX6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TDX6-F1-predicted_aligned_error_v6.png","plddt_mean":87.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSGALNACT1","jax_strain_url":"https://www.jax.org/strain/search?query=CSGALNACT1"},"sequence":{"accession":"Q8TDX6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TDX6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TDX6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TDX6"}},"corpus_meta":[{"pmid":"12446672","id":"PMC_12446672","title":"Differential roles of two N-acetylgalactosaminyltransferases, CSGalNAcT-1, and a novel enzyme, CSGalNAcT-2. Initiation and elongation in synthesis of chondroitin sulfate.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12446672","citation_count":89,"is_preprint":false},{"pmid":"21284936","id":"PMC_21284936","title":"Correlation of C4ST-1 and ChGn-2 expression with chondroitin sulfate chain elongation in atherosclerosis.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21284936","citation_count":34,"is_preprint":false},{"pmid":"28982363","id":"PMC_28982363","title":"Abnormalities in perineuronal nets and behavior in mice lacking CSGalNAcT1, a key enzyme in chondroitin sulfate synthesis.","date":"2017","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/28982363","citation_count":29,"is_preprint":false},{"pmid":"27599773","id":"PMC_27599773","title":"Chondroitin Sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT-1) Deficiency Results in a Mild Skeletal Dysplasia and Joint Laxity.","date":"2016","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/27599773","citation_count":20,"is_preprint":false},{"pmid":"28987564","id":"PMC_28987564","title":"Roles of CSGalNAcT1, a key enzyme in regulation of CS synthesis, in neuronal regeneration and plasticity.","date":"2017","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/28987564","citation_count":19,"is_preprint":false},{"pmid":"31705726","id":"PMC_31705726","title":"CSGALNACT1-congenital disorder of glycosylation: A mild skeletal dysplasia with advanced bone age.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31705726","citation_count":17,"is_preprint":false},{"pmid":"26806424","id":"PMC_26806424","title":"Chondroitin sulfate β-1,4-N-acetylgalactosaminyltransferase-1 (ChGn-1) polymorphism: Association with progression of multiple sclerosis.","date":"2016","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/26806424","citation_count":7,"is_preprint":false},{"pmid":"35322673","id":"PMC_35322673","title":"ChGn-2 Plays a Cardioprotective Role in Heart Failure Caused by Acute Pressure Overload.","date":"2022","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/35322673","citation_count":7,"is_preprint":false},{"pmid":"31325655","id":"PMC_31325655","title":"Biallelic CSGALNACT1-mutations cause a mild skeletal dysplasia.","date":"2019","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/31325655","citation_count":6,"is_preprint":false},{"pmid":"41996943","id":"PMC_41996943","title":"Impact of CSGALNACT1-mediated structural changes in chondroitin sulfate on tau seed uptake and pathological progression.","date":"2026","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/41996943","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.17.659865","title":"Genetic impacts on within-pair DNA methylation variance in monozygotic twins capture gene-environment interactions and cell-type effects","date":"2025-06-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.17.659865","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":7873,"output_tokens":1964,"usd":0.02654,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8911,"output_tokens":2344,"usd":0.051577,"stage2_stop_reason":"end_turn"},"total_usd":0.078117,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"CSGalNAcT-1 (CSGALNACT1) is a type II membrane protein with N-acetylgalactosaminyltransferase activity that initiates chondroitin sulfate (CS) chain synthesis by transferring GalNAc to the tetrasaccharide GAG-protein linker region (GlcA-Gal-Gal-Xyl-O-methoxyphenyl) with beta-1,4 linkage. Transfection of CSGalNAcT-1 into CHO cells shifted glycosaminoglycan composition on a syndecan-4/FGF-1 chimera from heparan sulfate to chondroitin sulfate, confirming its role in CS chain initiation in vivo.\",\n      \"method\": \"In vitro enzyme activity assay with CS poly/oligosaccharide substrates; CHO cell transfection with glycosaminoglycan composition analysis; 5'-RACE cloning\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic assay, cell-based transfection with defined biochemical readout, replicated substrate specificity comparisons\",\n      \"pmids\": [\"12446672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A missense mutation p.Pro384Arg in CSGALNACT1 causes reduced GalNAc-transferase activity of the CSGalNAcT-1 protein, establishing that this catalytic activity is required for normal CS chain biosynthesis and skeletal development; loss-of-function mutations cause a skeletal dysplasia reminiscent of Csgalnact1-/- mice.\",\n      \"method\": \"Biochemical GalNAc-transferase activity assay of mutant vs wild-type recombinant protein; clinical genetics (compound heterozygosity identified by sequencing); fibroblast proteoglycan synthesis analysis\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct enzymatic activity assay of mutant protein, supported by clinical genetics and mouse model consistency, single lab\",\n      \"pmids\": [\"27599773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CSGalNAcT1 (T1) knockout mice show ~50% reduction in CS content in brain regions, with diminished CS in perineuronal nets (PNNs) despite unchanged aggrecan core protein levels, demonstrating that CSGalNAcT1 is required for CS chain biosynthesis in PNNs and is necessary for normal ocular dominance plasticity onset and social/behavioral phenotypes.\",\n      \"method\": \"CSGalNAcT1 knockout mouse generation; biochemical quantification of CS by ELISA/disaccharide analysis; immunohistochemistry for PNN components; behavioral testing (open-field, acoustic startle, social preference)\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse with defined biochemical and behavioral phenotypes, multiple orthogonal methods across independent labs\",\n      \"pmids\": [\"28982363\", \"28987564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CSGalNAcT1 (T1) knockout mice show extensive axon regeneration following spinal cord injury, establishing that CS synthesized by T1 creates a physical and chemical barrier inhibiting axon growth after CNS injury.\",\n      \"method\": \"Spinal cord injury in T1 knockout mice with axon regeneration assessment\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined KO with specific cellular phenotype (axon regeneration), single lab, no orthogonal mechanistic confirmation in abstract\",\n      \"pmids\": [\"28987564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A coding SNP in CSGalNAcT-1 (p.S126L) results in complete loss of enzyme activity when expressed in COS-1 cells, identifying Ser-126 as functionally critical for catalytic activity.\",\n      \"method\": \"Expression of mutant ChGn-1 protein in COS-1 cells with GalNAc-transferase activity assay\",\n      \"journal\": \"Neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct enzyme activity assay in cells, single lab, single method reported in abstract\",\n      \"pmids\": [\"26806424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Novel missense variants p.Asp432Tyr and p.Asn264Ser in CSGALNACT1 result in significantly reduced CSGalNAcT-1 enzymatic activity, and patient fibroblasts show altered levels of chondroitin, dermatan, and heparan sulfate moieties, confirming that loss of CSGalNAcT-1 activity disrupts glycosaminoglycan biosynthesis.\",\n      \"method\": \"Biochemical GalNAc-transferase activity assay of recombinant mutant proteins; disaccharide analysis of GAG composition in patient fibroblasts; trio-exome sequencing\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct enzyme activity assay and cell-based GAG composition analysis, two orthogonal methods, single lab\",\n      \"pmids\": [\"31705726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CSGALNACT1 overexpression in Neuro2a cells enhances CS-dependent tau seed uptake, and CSGALNACT1-generated CS (enriched in non-sulfated O-unit disaccharides) shows high affinity for tau seeds and wild-type tau monomers and promotes tau aggregation in vitro, establishing that O-unit-enriched CS chains produced by CSGALNACT1 facilitate extracellular tau capture, cellular uptake, and aggregation.\",\n      \"method\": \"CSGALNACT1 overexpression in Neuro2a cells with tau seed uptake assay; disaccharide analysis of CS composition; in vitro tau aggregation assay with CS; CS-tau binding affinity measurement\",\n      \"journal\": \"Biochimica et biophysica acta. General subjects\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct in vitro binding and aggregation assays plus cell-based uptake assay with overexpression, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"41996943\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSGALNACT1 (CSGalNAcT-1/ChGn-1) is a Golgi-resident type II membrane GalNAc-transferase that catalyzes the initial step of chondroitin sulfate (CS) chain biosynthesis by transferring GalNAc in a beta-1,4 linkage to the GAG-protein linker tetrasaccharide; it generates O-unit-enriched CS chains that regulate perineuronal net formation, CNS axon regeneration inhibition after injury, synaptic plasticity, and—via high-affinity binding to tau—can facilitate tau seed uptake and aggregation, with loss-of-function mutations in humans causing skeletal dysplasia.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CSGALNACT1 (CSGalNAcT-1/ChGn-1) is a Golgi-type N-acetylgalactosaminyltransferase that initiates chondroitin sulfate (CS) chain biosynthesis by transferring GalNAc in a beta-1,4 linkage onto the GlcA-Gal-Gal-Xyl GAG-protein linker tetrasaccharide; ectopic expression shifts glycosaminoglycan output from heparan sulfate toward chondroitin sulfate, confirming its role in committing chains to the CS pathway in vivo [#0]. This catalytic activity is functionally critical: point mutations at residues such as Ser-126, Asn-264, Pro-384, and Asp-432 abolish or sharply reduce GalNAc-transferase activity and disrupt glycosaminoglycan composition in patient fibroblasts [#1, #4, #5], and biallelic loss-of-function variants in humans cause a skeletal dysplasia [#1, #5]. In the CNS, CSGalNAcT1 supplies CS chains for perineuronal nets, and its loss reduces brain CS by roughly half without affecting the aggrecan core protein, altering ocular dominance plasticity and social behavior [#2], while also generating the inhibitory CS barrier that limits axon regeneration after spinal cord injury [#3]. The CS chains produced by CSGalNAcT1 are enriched in non-sulfated O-unit disaccharides, which bind tau seeds and monomers with high affinity and promote tau capture, cellular uptake, and aggregation [#6].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established the founding biochemical activity: whether CSGalNAcT-1 initiates CS chain assembly was answered by showing it adds the first GalNAc to the linker tetrasaccharide and redirects GAG output toward chondroitin sulfate.\",\n      \"evidence\": \"In vitro GalNAc-transferase assay on linker substrates plus CHO transfection with GAG composition analysis on a syndecan-4/FGF-1 chimera\",\n      \"pmids\": [\"12446672\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of substrate recognition not resolved\", \"Relative contribution versus CSGalNAcT-2 in vivo not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected enzyme activity to disease and pinpointed catalytic residues: missense mutations (p.Pro384Arg; p.S126L) reduce or abolish GalNAc-transferase activity, establishing that the catalytic function is required for CS biosynthesis and skeletal development.\",\n      \"evidence\": \"Biochemical activity assays of recombinant/cell-expressed mutant proteins, clinical genetics, and fibroblast proteoglycan analysis\",\n      \"pmids\": [\"27599773\", \"26806424\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab activity measurements\", \"Structural explanation for residue criticality not provided\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the CNS requirement: knockout mice resolved whether CSGalNAcT1 is needed for CS in perineuronal nets and for plasticity, showing ~50% brain CS loss, depleted PNN CS, and altered ocular dominance plasticity and behavior.\",\n      \"evidence\": \"Knockout mouse with CS quantification, PNN immunohistochemistry, and behavioral testing\",\n      \"pmids\": [\"28982363\", \"28987564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking CS loss to specific behavioral phenotypes not dissected\", \"Cell-type-specific contributions not isolated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked the enzyme to injury repair: knockout mice showed extensive axon regeneration after spinal cord injury, establishing that CSGalNAcT1-synthesized CS forms an inhibitory barrier to CNS axon growth.\",\n      \"evidence\": \"Spinal cord injury in knockout mice with axon regeneration assessment\",\n      \"pmids\": [\"28987564\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No orthogonal mechanistic confirmation of the inhibitory mechanism\", \"Functional recovery outcomes not detailed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Broadened the disease/biochemistry link: additional missense variants (p.Asp432Tyr, p.Asn264Ser) reduce activity and disrupt chondroitin, dermatan, and heparan sulfate moieties in patient cells, confirming loss of activity perturbs glycosaminoglycan biosynthesis broadly.\",\n      \"evidence\": \"Recombinant mutant activity assays, fibroblast disaccharide analysis, and trio-exome sequencing\",\n      \"pmids\": [\"31705726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Genotype-phenotype correlation across patients not established\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined a disease-relevant downstream consequence: O-unit-enriched CS produced by CSGALNACT1 binds tau with high affinity and promotes its capture, uptake, and aggregation, linking the enzyme's chain output to tau pathology.\",\n      \"evidence\": \"Overexpression in Neuro2a cells with tau seed uptake assay, CS disaccharide analysis, in vitro tau aggregation, and CS-tau binding affinity measurement\",\n      \"pmids\": [\"41996943\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab in vitro/cell evidence not validated in vivo\", \"Relevance to human tauopathy progression not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CSGalNAcT1 activity is regulated, how O-unit-enriched chain composition is controlled, and the structural basis of its substrate specificity remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model in the corpus\", \"Regulation of chain sulfation pattern uncharacterized\", \"Functional division of labor with CSGalNAcT-2 unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 4, 5]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1630316\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":4,"faith_pct":100.0}}